Solu Therapeutics

Solu Therapeutics is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, pioneering a novel class of antibody therapeutics that unlock cell-surface targets by combining small molecules with effector antibodies through proprietary linker technology. Its two platform technologies are CyTAC (Cytotoxicity Targeting Chimera), which links cell-surface targets to antibodies that kill pathogenic cells, and TicTAC (Therapeutic Index Control Targeting Chimera), which gives long-acting small-molecule agonists and antagonists antibody-like pharmacokinetics. Its lead program, STX-0712, is a CyTAC targeting the GPCR CCR2 in Phase 1 trials for chronic myelomonocytic leukemia, with additional oncology and immunology programs advancing. Solu is a portfolio company of the venture firm DCVC. The company operates as a drug-discovery and clinical-development organization and publishes no public developer API, developer portal, or programmatic surface.

Solu Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Therapeutics, and Oncology.

🌐 Visit website 📡 Source on GitHub
9.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPharmaceuticalsTherapeuticsOncologyImmunologyAntibodiesDrug DiscoveryClinical Stage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 9.0/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/solu-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Solu Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: solu-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/solu-therapeutics.png
name: Solu Therapeutics
description: Solu Therapeutics is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, pioneering
  a novel class of antibody therapeutics that unlock cell-surface targets by combining small molecules with effector antibodies
  through proprietary linker technology. Its two platform technologies are CyTAC (Cytotoxicity Targeting Chimera), which links
  cell-surface targets to antibodies that kill pathogenic cells, and TicTAC (Therapeutic Index Control Targeting Chimera),
  which gives long-acting small-molecule agonists and antagonists antibody-like pharmacokinetics. Its lead program, STX-0712,
  is a CyTAC targeting the GPCR CCR2 in Phase 1 trials for chronic myelomonocytic leukemia, with additional oncology and immunology
  programs advancing. Solu is a portfolio company of the venture firm DCVC. The company operates as a drug-discovery and clinical-development
  organization and publishes no public developer API, developer portal, or programmatic surface.
url: https://raw.githubusercontent.com/api-evangelist/solu-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Oncology
- Immunology
- Antibodies
- Drug Discovery
- Clinical Stage
apis: []
common:
- type: DomainSecurity
  url: security/solu-therapeutics-domain-security.yml
- type: Website
  url: https://solutherapeutics.com
- type: PrivacyPolicy
  url: https://cdn.prod.website-files.com/669551ccc7908830b842dc2b/66a95195f579f49a0115e1db_Solu%20terms%20of%20use%20%26%20privacy%20policy.pdf
- type: TermsOfService
  url: https://cdn.prod.website-files.com/669551ccc7908830b842dc2b/66a95195f579f49a0115e1db_Solu%20terms%20of%20use%20%26%20privacy%20policy.pdf
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1